DFTX
Definium Therapeutics, Inc.
$32.97
+2.71% 2026-10-19
Healthcare
DFTXSPY
1W
-6.3%
1M
-15.0%
3M
-23.0%
6M
+42.2%
YTD
+146.2%
1Y
+141.5%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$4.4B
P/E (trailing)–
P/E (forward)-17.0
52-week range10.46 – 49.70
Revenue growth (YoY, latest qtr)–
Dividend yield0.00%
Analyst consensusStrong Buy (18)
Mean price target$72.33 (+119%)
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-05 · during market · EPS est -0.56
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.55 | -1.44 | -162.2% |
| 2026-05-07 | -0.49 | -0.71 | -44.0% |
| 2026-02-26 | -0.49 | -0.50 | -2.0% |
| 2025-11-06 | -0.50 | -0.78 | -54.8% |
| 2025-07-31 | -0.36 | -0.50 | -38.3% |
| 2025-05-08 | -0.37 | -0.35 | +4.3% |
| 2025-03-06 | -0.28 | -0.41 | -47.2% |
| 2024-11-07 | -0.26 | -0.18 | +31.6% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Analyst actions
JP Morgan
PT $84
2026-10-09 · init
→ OverweightPT $84
Canaccord Genuity
PT $78
2026-09-15 · main
Buy → BuyPT $78
Baird
PT $79
2026-09-15 · main
Outperform → OutperformPT $79
HC Wainwright & Co.
PT $70
2026-09-14 · reit
Buy → BuyPT $70
Needham
PT $66
2026-09-14 · reit
Buy → BuyPT $66
RBC Capital
PT $66
2026-09-11 · reit
Outperform → OutperformPT $66
Insider trades
Karlin Daniel
$396.9K
Director, Chief Medical Officer · 2026-09-25
SELL$396.9K
Barrow Robert
$1.2M
Director, Chief Executive Officer · 2026-09-25
SELL$1.2M
Wiley Matthew T.
$113.3K
Chief Commercial Officer · 2026-09-25
SELL$113.3K
Sullivan Mark
$513.8K
Chief Legal Officer · 2026-09-25
SELL$513.8K
Roberts Brandi
$123.5K
Chief Financial Officer · 2026-09-25
SELL$123.5K
Barrow Robert
$721.7K
Director, Chief Executive Officer · 2026-09-03
SELL$721.7K
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
News
Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value
Simply Wall St. · 14h ago
Definium Therapeutics Investors Remain Concerned Over Psychedelics' Commercial Scalability, RBC Says
MT Newswires · 21h ago
Definium Therapeutics Announces New Employee Inducement Grants
Business Wire · Oct 13
JPMorgan Initiates Coverage on Definium Therapeutics With Overweight Rating, $84 Price Target
MT Newswires · Oct 09
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com · Sep 30
Definium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC Filing
MT Newswires · Sep 30
Definium Therapeutics Announces New Employee Inducement Grants
Business Wire · Sep 28
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
MarketBeat · Sep 24
Stats refreshed 2026-10-19 19:02:43 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.